Cited by 2,217CAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Open access

Liu, Enli, Marin, David, Banerjee, Pinaki, Macapinlac, Homer A., Thompson, Philip, Basar, Rafet, Nassif Kerbauy, Lucila, Overman, Bethany, Thall, Peter, Kaplan, Mecit, Nandivada, Vandana, Kaur, Indresh, Nunez Cortes, Ana, Cao, Kai, Daher, May, Hosing, Chitra, Cohen, Evan N., Kebriaei, Partow, Mehta, Rohtesh, Neelapu, Sattva, Nieto, Yago, Wang, Michael, Wierda, William, Keating, Michael, Champlin, Richard, Shpall, Elizabeth J., Rezvani, Katayoun·2020·New England Journal of Medicine

DOI 10.1056/nejmoa1910607PMC PMC7101242

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy. RESULTS: The administration of CAR-NK cells was not associated with the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. The maximum tolerated dose was not reached. Of the 11 patients who were treated, 8 (73%) had a response; of these patients, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transformation component but had persistent CLL. Responses were rapid and seen within 30 days after infusion at all dose levels. The infused CAR-NK cells expanded and persisted at low levels for at least 12 months. CONCLUSIONS: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1910607

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citation
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citation
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 101–200 of 1,000

Forks in the road for CAR T and CAR NK cell cancer therapies
Dagher, O. K., & Posey, A. D. (2023) · Nature Immunology · doi:10.1038/s41590-023-01659-y · Cited by 192
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
Wang, W., Liu, Y., He, Z., Li, L., Liu, S., Jiang, M., Zhao, B., Deng, M., Wang, W., Ge, X., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01815-9 · Cited by 197
New agents and regimens for diffuse large B cell lymphoma
Wang, L., Li, L., & Young, K. H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01011-z · Cited by 174
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
Samra, B., Jabbour, E. J., Ravandi, F., Kantarjian, H. M., & Short, N. J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00905-2 · Cited by 176
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines
Zhang, L., Zuris, J. A., Viswanathan, R., Edelstein, J., Turk, R., Thommandru, B., Rube, H. T., Glenn, S. E., Collingwood, M. A., Bode, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24017-8 · Cited by 170
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Kerbauy, L. N., Marín, N. D., Kaplan, M., Banerjee, P. P., Berrien-Elliott, M. M., Becker‐Hapak, M., Başar, R., Foster, M., Melo, L. G., Neal, C. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0164 · Cited by 156
Self-citation
CAR-NK Cells in the Treatment of Solid Tumors
Wrona, E., Borowiec, M., & Potemski, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115899 · Cited by 158
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
Bell, M. R., & Gottschalk, S. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684642 · Cited by 164
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies
Market, M., Angka, L., Martel, A. B., Bastin, D. J., Olanubi, O., Tennakoon, G., Boucher, D. M., Ng, J., Ardolino, M., & Auer, R. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01512 · Cited by 158
Leveraging NKG2D Ligands in Immuno-Oncology
Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 152
CAR-NK Cells: From Natural Basis to Design for Kill
Khawar, M. B., & Sun, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707542 · Cited by 164
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 166
Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
Morgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 153
Human natural killer cells: Form, function, and development
Mace, E. M. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.09.022 · Cited by 157
CAR‐NK cell in cancer immunotherapy; A promising frontier
Marofi, F., Abdul‐Rasheed, O. F., Rahman, H. S., Budi, H. S., Jalil, A. T., Yumashev, A. V., Hassanzadeh, A., Yazdanifar, M., Motavalli, R., Chartrand, M. S., et al. (2021) · Cancer Science · doi:10.1111/cas.14993 · Cited by 149
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
Bedoya, D. M., Dutoit, V., & Migliorini, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640082 · Cited by 151
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
Burger, M. C., Forster, M.-T., Romanski, A., Straßheimer, F., Macas, J., Zeiner, P. S., Steidl, E., Herkt, S. C., Weber, K. J., Schupp, J., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad087 · Cited by 146
Cancer immunotherapy comes of age and looks for maturity
Finck, A., Gill, S. I., & June, C. H. (2020) · Nature Communications · doi:10.1038/s41467-020-17140-5 · Cited by 143
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 154
Engineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 148
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
Blazar, B. R., Hill, G. R., & Murphy, W. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0356-4 · Cited by 148
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
Demaria, O., Gauthier, L., Debroas, G., & Vivier, É. (2021) · European Journal of Immunology · doi:10.1002/eji.202048953 · Cited by 152
Potential solutions for manufacture of CAR T cells in cancer immunotherapy
Blache, U., Popp, G., Dünkel, A., Koehl, U., & Fricke, S. (2022) · Nature Communications · doi:10.1038/s41467-022-32866-0 · Cited by 146
Next-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002547 · Cited by 145
Self-citation
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
Funk, C. R., Wang, S., Chen, K. Z., Waller, A., Sharma, A., Edgar, C. L., Gupta, V. A., Chandrakasan, S., Zoine, J. T., Fedanov, A., et al. (2022) · Blood · doi:10.1182/blood.2021011597 · Cited by 146
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
Leivas, A., Valeri, A., Córdoba, L., García-Ortiz, A., Ortiz, A., Sánchez-Vega, L., Graña-Castro, O., Fernández, L., Carreño-Tarragona, G., Pérez, M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00537-w · Cited by 139
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Tapia‐Galisteo, A., Álvarez‐Vallina, L., & Sanz, L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01482-w · Cited by 147
Regulation of natural killer cell activity by glucocorticoids, serotonin, dopamine, and epinephrine
Capellino, S., Claus, M., & Watzl, C. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0477-9 · Cited by 144
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
Cliff, E. R. S., Kelkar, A. H., Russler‐Germain, D. A., Tessema, F. A., Raymakers, A., Feldman, W. B., & Kesselheim, A. S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_397912 · Cited by 150
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Liu, Y., Zhou, X., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01134-x · Cited by 142
Off-the-Shelf Prostate Stem Cell Antigen–Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer
Teng, K., Mansour, A. G., Zhu, Z. G., Li, Z., Tian, L., Ma, S., Xu, B., Lu, T., Chen, H., Hou, D., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.281 · Cited by 136
Allogeneic CAR Cell Therapy—More Than a Pipe Dream
Caldwell, K. J., Gottschalk, S. M., & Talleur, A. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618427 · Cited by 141
Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia
Dong, H., Ham, J. D., Hu, G., Xie, G., Vergara, J. A., Liang, Y., Ali, A. K., Tarannum, M., Donner, H., Bagińska, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122379119 · Cited by 132
Game changers in science and technology - now and beyond
Betz, U. A. K., Arora, L., Assal, R. A., de Azevedo, H. F. Z., Baldwin, J., Becker, M. S., Bostock, S., Cheng, V. W. T., Egle, T., Ferrari, N., et al. (2023) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2023.122588 · Cited by 153
Direct in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 141
NK cell exhaustion in the tumor microenvironment
Hao, J., Yang, H., Xiong, H., & Luo, K. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303605 · Cited by 131
Clonal expansion of innate and adaptive lymphocytes
Adams, N. M., Grassmann, S. A., & Sun, J. C.-Y. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0307-4 · Cited by 129
Theranostic cells: emerging clinical applications of synthetic biology
McNerney, M. P., Doiron, K. E., Ng, T. L., Chang, T. Z., & Silver, P. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00383-3 · Cited by 131
BiTEs better than CAR T cells
Subklewe, M. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001792 · Cited by 129
CAR‐NK cells: the next wave of cellular therapy for cancer
Daher, M., Garcia, L. M., Li, Y., & Rezvani, K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1274 · Cited by 133
Self-citation
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia
Berrien-Elliott, M. M., Foltz, J. A., Russler‐Germain, D. A., Neal, C. C., Tran, J., Gang, M., Wong, P., Fisk, B. A., Cubitt, C. C., Marín, N. D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm1375 · Cited by 134
All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity
Ramírez-Labrada, A., Pesini, C., Santiago, L., Hidalgo, S., Calvo-Pérez, A., Oñate, C., Andrés-Tovar, A., Garzón-Tituaña, M., Uranga-Murillo, I., Arias, M. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896228 · Cited by 146
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 131
Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications
Terrén, I., Orrantia, A., Astarloa-Pando, G., Amarilla-Irusta, A., Zenarruzabeitia, O., & Borrego, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884648 · Cited by 123
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Caruso, S., Angelis, B. D., Bufalo, F. D., Ciccone, R., Donsante, S., Volpe, G., Manni, S., Guercio, M., Pezzella, M., Iaffaldano, L., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01376-3 · Cited by 126
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Liu, Q., Li, J., Zheng, H., Yang, S., Hua, Y., Huang, N., Kleeff, J. H., Liao, Q., & Wu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01735-9 · Cited by 133
Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation
Yao, L., Hou, J., Wu, X., Lu, Y., Jin, Z., Yu, Z., Yu, B., Li, J., Yang, Z., Li, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102923 · Cited by 137
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 131
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method
Li, Y.-R., Zhou, Y., Yu, J., Kim, K. G., Li, M., Lee, D., Zhou, K., Chen, Y., Zhu, Y., Wang, Y.-C., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02226-y · Cited by 131
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
Rafei, H., Daher, M., & Rezvani, K. (2020) · British Journal of Haematology · doi:10.1111/bjh.17186 · Cited by 121
Self-citation
Natural killer cell-based immunotherapy for acute myeloid leukemia
Xu, J., & Niu, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00996-x · Cited by 115
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
Hadiloo, K., Taremi, S., Heidari, M., & Esmaeilzadeh, A. (2023) · Biomarker Research · doi:10.1186/s40364-023-00537-x · Cited by 128
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
Lü, H., Zhao, X., Li, Z., Hu, Y., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720501 · Cited by 121
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Li, L., Mohanty, V., Dou, J., Huang, Y., Banerjee, P. P., Miao, Q., Lohr, J. G., Vijaykumar, T., Frede, J., Knoechel, B., et al. (2023) · Science Advances · doi:10.1126/sciadv.add6997 · Cited by 120
Self-citation
Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity
Ruf, B., Greten, T. F., & Korangy, F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00562-w · Cited by 119
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 123
Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions
Zhong, Y., & Liu, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02077-1 · Cited by 116
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
Dai, H., Zhu, C., Huai, Q., Xu, W., Zhu, J., Zhang, X., Zhang, X., Sun, B., Xu, H., Zheng, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.034 · Cited by 114
Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance
Hashemi, E., & Malarkannan, S. (2020) · Cancers · doi:10.3390/cancers12061553 · Cited by 121
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Arvindam, U. S., van Hauten, P. M. M., Schirm, D. K., Schaap, N. P., Hobo, W. A., Blazar, B. R., Vallera, D. A., Dolstra, H., Felices, M., & Miller, J. S. (2020) · Leukemia · doi:10.1038/s41375-020-01065-5 · Cited by 114
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 124
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
Gurney, M. E., Stikvoort, A., Nolan, E., Kirkham-McCarthy, L., Khoruzhenko, S., Shivakumar, R., Zweegman, S., van de Donk, N. W. C. J., Mutis, T., Szegezdi, É., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.271908 · Cited by 116
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Pfefferle, A., & Huntington, N. D. (2020) · Cancers · doi:10.3390/cancers12030706 · Cited by 117
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
Albinger, N., Pfeifer, R., Nitsche, M., Mertlitz, S., Campe, J., Stein, K., Kreyenberg, H., Schubert, R., Quadflieg, M., Schneider, D., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00660-2 · Cited by 117
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy
Li, Y.-R., Zhou, Y., Kim, K. G., Zhu, Y., Ma, F., Yu, J., Wang, Y.-C., Chen, X., Li, Z., Zeng, S., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100449 · Cited by 118
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy
Berrien-Elliott, M. M., Becker‐Hapak, M., Cashen, A. F., Jacobs, M. T., Wong, P., Foster, M., McClain, E. D., Desai, S., Pence, P., Cooley, S., et al. (2021) · Blood · doi:10.1182/blood.2021011532 · Cited by 111
Therapeutic potential of CAR T cell in malignancies: A scoping review
Mehrabadi, A. Z., Ranjbar, R., Farzanehpour, M., Shahriary, A., Dorostkar, R., Hamidinejad, M. A., & Ghaleh, H. E. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112512 · Cited by 116
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
Fischer, J. W., & Bhattarai, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693016 · Cited by 113
Current state and next-generation CAR-T cells in multiple myeloma
Manier, S., Ingegnere, T., Escure, G., Prodhomme, C., Nudel, M., Mitra, S., & Facon, T. T. F. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100929 · Cited by 115
In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery
Ye, Z., Chen, J., Zhao, X., Li, Y., Harmon, J., Huang, C., Chen, J., & Xu, Q. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01532 · Cited by 110
Adoptive cell therapy for cancer treatment
Du, S., Yan, J., Xue, Y., Zhong, Y., & Dong, Y. (2023) · Exploration · doi:10.1002/exp.20210058 · Cited by 123
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00402 · Cited by 112
Engineering the next generation of CAR-NK immunotherapies
Biederstädt, A., & Rezvani, K. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03209-4 · Cited by 114
Self-citation
Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death
Li, Z., Ma, R., Tang, H., Guo, J., Shah, Z., Zhang, J., Liu, N., Cao, S., Marcucci, G., Artis, D., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.015 · Cited by 115
Engineering NK Cells for CAR Therapy—Recent Advances in Gene Transfer Methodology
Schmidt, P., Raftery, M. J., & Pecher, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611163 · Cited by 106
Natural Killer Cells: Tumor Surveillance and Signaling
Guzman, L. G. M., Keating, N., & Nicholson, S. E. (2020) · Cancers · doi:10.3390/cancers12040952 · Cited by 118
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells
Sanber, K. S., Savani, B. N., & Jain, T. (2021) · British Journal of Haematology · doi:10.1111/bjh.17544 · Cited by 111
EBV-associated diseases: Current therapeutics and emerging technologies
Chakravorty, S., Afzali, B., & Kazemian, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059133 · Cited by 114
NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions
Luo, H., Zhou, Y., Zhang, J., Zhang, Y., Long, S., Lin, X., Yang, A., Duan, J., Yang, N. Y., Yang, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1087689 · Cited by 105
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences
Vitale, C., & Strati, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00849 · Cited by 103
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine
den Bossche, V. V., Zaryouh, H., Vara-Messler, M., Vignau, J., Machiels, J., Wouters, A., Schmitz, S., & Corbet, C. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100806 · Cited by 105
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
Shanley, M., Daher, M., Dou, J., Li, S., Başar, R., Rafei, H., Dede, M., Gumin, J., Garcίa, J. P., Cortes, A. K. N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.007 · Cited by 102
Self-citation
Immunogenic Cell Death-Based Cancer Vaccines
Jin, M.-Z., & Wang, X.-P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697964 · Cited by 99
“CAR-NK therapy received great therapeutic responses in 11 enrolled relapsed or refractory CD19-positive cancers, without inducing major immune related adverse effects (irAE) (11).”
Background
Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells
Morandi, F., Yazdanifar, M., Cocco, C., Bertaina, A., & Airoldi, I. (2020) · Cells · doi:10.3390/cells9081757 · Cited by 103
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models
Vaisitti, T., Arruga, F., Vitale, N., Lee, T.-T., Ko, M., Chadburn, A., Braggio, E., Napoli, A. D., Iannello, A., Allan, J. N., et al. (2021) · Blood · doi:10.1182/blood.2020008404 · Cited by 98
Adoptive Immunotherapy beyond CAR T-Cells
Titov, A., Zmievskaya, E., Ganeeva, I., Valiullina, A., Petukhov, A., Rakhmatullina, A., Рифкатовна, М. Р., Fainshtein, M., Rizvanov, A. A., & Bulatov, E. (2021) · Cancers · doi:10.3390/cancers13040743 · Cited by 101
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
Ng, Y. Y., Du, Z., Zhang, X., Chng, W. J., & Wang, S. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00365-x · Cited by 98
Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
Cao, B., Liu, M., Huang, J., Zhou, J., Li, J., Lian, H., Huang, W., Guo, Y., Yang, S., Lin, L., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64630 · Cited by 100
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 96
NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential
Portale, F., & Mitri, D. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119521 · Cited by 109
Memory-like natural killer cells for cancer immunotherapy
Gang, M., Wong, P., Berrien-Elliott, M. M., & Fehniger, T. A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.11.003 · Cited by 100
Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies
Zhang, J., Webster, S. F., Duffin, B. M., Bernstein, M. N., Steill, J., Swanson, S. A., Forsberg, M. H., Bolin, J. M., Brown, M. E., Majumder, A., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.12.012 · Cited by 100
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Yang, Y., Badeti, S., Hsiang-Chi, T., Ma, M. T., Liu, T., Jiang, J., Liu, C., & Liu, D. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.014 · Cited by 96
The EBMT/EHA CAR-T Cell Handbook
Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 106
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
Zalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 100
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
Liu, K., Cui, J., Zhan, Y., Ouyang, Q., Lu, Q., Yang, D., Li, X., & Yin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01561-5 · Cited by 100

Authors: Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., Nandivada, V., Kaur, I., Nunez Cortes, A., Cao, K., Daher, M., Hosing, C., Cohen, E. N., Kebriaei, P., Mehta, R., Neelapu, S., Nieto, Y., Wang, M., Wierda, W., Keating, M., Champlin, R., Shpall, E. J., & Rezvani, K.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Stem Cell Transplantation and Cellular Therapy (E.L., D.M., P.B., R.B., L.N.K., B.O., M. Kaplan, V.N., I.K., A.N.C., M.D., C.H., P.K., R.M., Y.N., R.C., E.J.S., K.R.), Nuclear Medicine (H.A.M.), Leukemia (P. Thompson, W.W., M. Keating), Biostatistics (P. Thall), Laboratory Medicine (K.C.), Hematopathology (E.N.C.), and Lymphoma and Myeloma (S.N., M.W.), University of Texas M.D. Anderson Cancer Center, Houston.
ORCID: Liu, Enli
Banerjee, Pinaki
Macapinlac, Homer A.
Thompson, Philip
Thall, Peter
Kaplan, Mecit
Cao, Kai
Daher, May
Hosing, Chitra
Cohen, Evan N.
Kebriaei, Partow
Mehta, Rohtesh
Neelapu, Sattva
Nieto, Yago
Wang, Michael
Wierda, William
Keating, Michael
Champlin, Richard
Shpall, Elizabeth J.
Rezvani, Katayoun
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-02-06
Volume: 382
Issue: 6
Pages: 545-553
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1910607
PMC: PMC7101242
OpenAlex: W3004611567
Cited by: 2,217
References: 37
Citations by year: 2026: 282 · 2025: 337 · 2024: 332 · 2023: 323 · 2022: 353 · 2021: 379 · 2020: 205
FWCI: 113.83
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: M.D. Anderson Cancer Center CLL and lymphoma Moonshot Grants
National Institutes of Health (1 R01 CA211044-01, 5P01CA148600-03, CA016672, P50CA100632-16)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CAR-NK cells, chimeric antigen receptor, natural killer cells, anti-CD19, relapsed or refractory B-cell lymphoma, chronic lymphocytic leukemia, Richter transformation, lymphodepleting chemotherapy, cytokine release syndrome, neurotoxicity, graft-versus-host disease, interleukin-6, CAR T-cell toxicity
MeSH terms: Receptors, Chimeric Antigen, Aged, Female, Fetal Blood, Genetic Vectors, Humans, Killer Cells, Natural, Lymphoma, Non-Hodgkin, Male, Middle Aged, Remission Induction, Retroviridae, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Transplantation Conditioning, Allografts, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks